Amprion exhibits at the MDS International Congress on Parkinson’s Disease and Movement Disorders in Madrid and presents scientific information on the SYNTap® test at Prion2022


“The SYNTap assay fills the void for a highly sensitive and specific clinical diagnostic tool” -Amprion Chief Scientific Officer Claudio Soto, Ph.D.

Amprion, a leader in the diagnosis of neurodegenerative diseases, invites researchers and practitioners attending MDS to visit Amprion at booth #212. We look forward to discussing how the SYNTap® Biomarker Test addresses the unmet medical need for a validated clinical test to diagnose Parkinson’s disease (PD) and differentiate PD from atypical Parkinson’s disease at an early stage. . Accurate and early diagnosis can accelerate personalized treatments and therapeutic innovations.

The urgent medical need for accurate and early diagnosis of neurodegenerative diseases increases as the world’s population ages. For every thousand people, 1 to 2 people are affected by Parkinson’s disease. The prevalence of PD increases with age, affecting 1% of the population aged 60 and over. Worldwide, about 10 million people could have PD.

Amprion’s SYNTap biomarker test helps physicians diagnose and differentiate complex and often confusing neurodegenerative diseases, including Parkinson’s disease, Lewy body variant of Alzheimer’s disease, Lewy body dementia, mild cognitive impairment with Lewy bodies and multiple system atrophy. The company’s proprietary detection technology, Seed Amplification Assay (SAA), accurately detects misfolded α-synuclein aggregates, a crucial biomarker associated with these devastating conditions.

“The SYNTap test fills the void for a highly sensitive and specific clinical diagnostic tool,” said Claudio Soto, Ph.D., Chief Scientific Officer of Amprion, who will speak at Prion2022, September 13-16 in Göttingen, in Germany. According to Russ Lebovitz, MD/Ph.D, CEO of Amprion, “Sound diagnosis enables the optimization of personalized treatment and disease management strategies for people with Parkinson’s disease and movement disorders. Dr. Lebovitz will attend MDS, International Congress on Parkinson’s Disease and Movement Disorders in Madrid, September 15-18.

Amprion will host a Meet the Expert session where attendees can discuss the science behind how the SYNTap assay performs in a clinical setting.

MEET THE EXPERT – Friday, September 15 – 10 a.m. to 12 p.m. – Booth #212

Neurologist Brit Mollenhauer, MD, specializes in Parkinson’s disease and movement disorders and directs translational research at the Paracelsus-Elena Klinik (PEKK) in Germany. It has developed a study center for clinical trials and translational research and works closely with the Michael J. Fox Foundation for Parkinson’s Disease Research.

“The AAS developed by Amprion offers highly accurate detection of misfolded synuclein in cerebrospinal fluid (CSF), which can serve as a diagnostic for patients suspected of having Parkinson’s disease, Lewy body dementia and multiple system atrophy, all of which are disorders of synuclein aggregation.”

Dr. Mollenhauer will discuss the value of Amprion’s SYNTap test in the early identification of synucleinopathy based on his studies: “We have shown that in one of our cohorts of patients with REM sleep behavior disorder (RBD), a prodromal condition of synuclein aggregation disorders, the SYNTap test can detect misfolded synuclein at least a decade before a clinical diagnosis of synuclein aggregation disorders can be made.

We look forward to meeting you at MDS Booth #212.

Download the SYNTap test data sheet.


A leader in the science of prion detection™, Amprion innovates biomarker testing for brain disease. Our SYNTap® biomarker test helps diagnose Parkinson’s disease, Lewy body dementia and Lewy body variant Alzheimer’s disease. Amprion has received FDA Breakthrough Device Designation for detecting misfolded synuclein in CSF. We strive to accelerate personalized medicine for neurodegenerative diseases through molecular testing.

Share the article on social networks or by e-mail:

Source link

Comments are closed.